Historique
Article de Périodique
Injecting human growth hormone as a performance-enhancing drug - perspectives from the United Kingdom (2009)
Auteur(s) :
M. EVANS-BROWN ;
J. McVEIGH
Article en page(s) :
267-288
Sous-type de document :
Revue de la littérature / Literature review
Domaine :
Dopage / Doping
Langue(s) :
Anglais
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus mots-clés
HORMONE DE CROISSANCE
;
PERFORMANCE
;
INJECTION
;
REDUCTION DES RISQUES ET DES DOMMAGES
;
DOPAGE
;
COUT
;
EFFET SECONDAIRE
;
ADULTERANT
Thésaurus géographique
ROYAUME-UNI
Note générale :
Journal of Substance Use, 2009, 14, (5), 267-288
Résumé :
ENGLISH :
Injectable human growth hormone has been used as a performance-enhancing drug in the United Kingdom since at least the mid-1980s. However, because of its prohibitive cost and limited supply it was initially restricted to a relatively small number of people. More recently data suggest that there has been a large increase in the use of the hormone within some sections of the general population. Here the hormone is usually taken as part of a high-dose polydrug regimen (which includes multiple types of anabolic steroids) predominately to enhance physique and/or bodily aesthetics. However, detailed systematic studies of the cultural diffusion of this drug (including the motivations for use, prevalence, patterns of use, and supply network) are lacking. Moreover, questions about growth hormone's efficacy, effectiveness, and safety (including risks from injecting and the use of adulterated products) when used as a performance-enhancing drug remain largely unanswered. This article reviews the data that are available on the self-directed use of growth hormone in the United Kingdom and the associated risks to individual and public health. (Author' s abstract)
ENGLISH :
Injectable human growth hormone has been used as a performance-enhancing drug in the United Kingdom since at least the mid-1980s. However, because of its prohibitive cost and limited supply it was initially restricted to a relatively small number of people. More recently data suggest that there has been a large increase in the use of the hormone within some sections of the general population. Here the hormone is usually taken as part of a high-dose polydrug regimen (which includes multiple types of anabolic steroids) predominately to enhance physique and/or bodily aesthetics. However, detailed systematic studies of the cultural diffusion of this drug (including the motivations for use, prevalence, patterns of use, and supply network) are lacking. Moreover, questions about growth hormone's efficacy, effectiveness, and safety (including risks from injecting and the use of adulterated products) when used as a performance-enhancing drug remain largely unanswered. This article reviews the data that are available on the self-directed use of growth hormone in the United Kingdom and the associated risks to individual and public health. (Author' s abstract)
Affiliation :
Royaume-Uni. United Kingdom.